OSR Holdings shares are trading higher after its unit Vaximm entered a non-binding term sheet with BCM Europe to explore a potential exclusive global licensing agreement for its VXM01 oral cancer immunotherapy platform.
OSR Holdings shares are trading higher after its unit Vaximm entered a non-binding term sheet with BCM Europe to explore a potential exclusive global licensing agreement for its VXM01 oral cancer immunotherapy platform.